{"$schema": "https://iptc.org/std/ninjs/ninjs-schema_3.2.json", "uri": "urn:newsml:wireva.mib.news:story:6937d673-0cd3-4942-ac2d-c0922656e564", "type": "composite", "version": "1", "versioncreated": "2026-11-17T05:45:15.235318Z", "firstcreated": "2026-11-17T05:45:15.235318Z", "pubstatus": "usable", "language": "uk", "headline": "Vivos Therapeutics отримала зростання виручки у третьому кварталі та відновила відповідність вимогам Nasdaq", "description_text": "Виробник внутрішньоротових апаратів для лікування апное сну звітує про зростання виручки за третій квартал і повернув відповідність вимогам біржі Nasdaq.", "associations": {"item-0": {"$schema": "https://iptc.org/std/ninjs/ninjs-schema_3.2.json", "uri": "urn:newsml:wireva.mib.news:item:d467cc98-d1e0-4bdb-bf2c-abd517db0d7a", "type": "text", "profile": "standard", "version": "1", "versioncreated": "2026-11-17T05:45:41.109562Z", "firstcreated": "2026-11-17T05:45:15.235318Z", "pubstatus": "usable", "urgency": 5, "language": "uk", "headline": "Vivos Therapeutics отримала зростання виручки у третьому кварталі та відновила відповідність вимогам Nasdaq", "byline": "Валентин Антоненко", "located": "Ukraine", "copyrightholder": "Haydamax OÜ", "copyrightnotice": "Wireva / Контрактова", "usageterms": "Subscribers may republish this item in full, including translation and trimming, with the credit “Wireva / Контрактова”. Set rel=canonical to https://kontraktova.com/biznes/vivos-therapeutics-otrimala-zrostannia-viruchki-u-tretomu-kvartali-ta-vidnovila-vidpovidnist-vimogam-nasdaq/ when publishing on the web.", "description_text": "Виробник внутрішньоротових апаратів для лікування апное сну звітує про зростання виручки за третій квартал і повернув відповідність вимогам біржі Nasdaq.", "altids": {"mosaic": "d467cc98-d1e0-4bdb-bf2c-abd517db0d7a", "story": "6937d673-0cd3-4942-ac2d-c0922656e564", "slug": "vivos-therapeutics-otrimala-zrostannia-viruchki-u-tretomu-kvartali-ta-vidnovila-vidpovidnist-vimogam-nasdaq"}, "subject": [{"name": "Economy and business", "rel": "direct", "literal": "economy", "code": "medtop:04000000", "scheme": "http://cv.iptc.org/newscodes/mediatopic/", "uri": "http://cv.iptc.org/newscodes/mediatopic/04000000"}], "place": [{"name": "Ukraine", "literal": "ua", "code": "UA", "scheme": "http://cv.iptc.org/newscodes/countrycodes/"}], "person": [], "organisation": [], "genre": [{"name": "Standard story", "literal": "standard"}], "service": [{"name": "Wireva", "literal": "wireva"}], "associations": {"featuremedia": {"uri": "urn:newsml:wireva.mib.news:media:364a8eb7-b79d-4d95-8127-2302ce78d2b3", "type": "picture", "version": "1", "pubstatus": "usable", "headline": "KNR Constructions Q2 FY27 slides: asset sales boost profits amid revenue decline", "description_text": "KNR Constructions за II квартал FY27 збільшила прибуток завдяки продажу активів на тлі падіння виручки", "copyrightholder": "content-media.investing.com", "copyrightnotice": "KNR Constructions Q2 FY27 slides: asset sales boost profits amid revenue decline", "usageterms": "Picture belongs to the source publication: address and terms are delivered, the file is not.", "altids": {"wireva": "364a8eb7-b79d-4d95-8127-2302ce78d2b3"}, "extra": {"wireva:delivery_mode": "link_only", "wireva:rights": {"licence": "", "licence_url": "", "licence_raw": "RSS source", "licence_verified_at": "2026-11-17T05:45:41.129497Z", "attribution_required": true, "attribution_text": "KNR Constructions Q2 FY27 slides: asset sales boost profits amid revenue decline", "redistribution_allowed": false, "commercial_use_allowed": false, "modifications_allowed": false, "share_alike_required": false}, "wireva:provenance": {"creator": "", "source_name": "content-media.investing.com", "source_url": "https://content-media.investing.com/news/LYNXMPEM3Q0HO_1200_L.jpg", "source_page_url": "https://content-media.investing.com/news/LYNXMPEM3Q0HO_1200_L.jpg", "our_page_url": "https://kontraktova.com/biznes/vivos-therapeutics-otrimala-zrostannia-viruchki-u-tretomu-kvartali-ta-vidnovila-vidpovidnist-vimogam-nasdaq/"}, "wireva:role": "lead"}, "renditions": {"source": {"href": "https://content-media.investing.com/news/LYNXMPEM3Q0HO_1200_L.jpg", "mimetype": "image/jpeg"}}}}, "extra": {"wireva:story": {"uri": "urn:newsml:wireva.mib.news:story:6937d673-0cd3-4942-ac2d-c0922656e564", "slug": "vivos-therapeutics-nasdaq-20261117", "status": "developing", "languages": ["uk"], "item_count": 1, "is_breaking": false}, "wireva:rights": {"class": "agency_original", "redistribution_allowed": false, "commercial_use_allowed": false, "modifications_allowed": true, "share_alike_required": false, "attribution_required": true, "attribution_text": "Wireva / Контрактова", "canonical_required": true, "canonical_url": "https://kontraktova.com/biznes/vivos-therapeutics-otrimala-zrostannia-viruchki-u-tretomu-kvartali-ta-vidnovila-vidpovidnist-vimogam-nasdaq/", "linkback_required": true, "licence": "", "licence_url": "", "licensor": "Haydamax OÜ", "valid_until": null, "excerpt_max_chars": 0, "decided_by_rule": "agency_original_borderline", "needs_review": true}, "wireva:provenance": {"production_method": "automated", "ai_stages": {"editing": true, "drafting": true, "headline": true, "discovery": true, "classification": true, "image_selection": true, "source_collection": true, "cross_source_comparison": true}, "model": "", "human_reviewed": false, "reviewed_by": "", "reviewed_at": null, "editorial_control": true, "editorial_responsibility": "Haydamax OÜ (Wireva)", "factchecked": false, "verification_status": "single_source", "independent_confirmations": 0, "official_source_used": false, "used_press_release": false, "public_interest": true, "ai_disclosure_required": true, "ai_disclosure_text": "Матеріал підготовлено за допомогою ШІ під редакційною відповідальністю Haydamax OÜ.", "independence_check": {"status": "borderline", "score": 0.375, "checked_at": "2026-11-17T05:45:41.123966Z"}, "sources": [{"url": "https://www.investing.com/news/company-news/vivos-therapeutics-reports-q3-revenue-growth-regains-nasdaq-compliance-93CH-5031269", "title": "Vivos Therapeutics reports Q3 revenue growth, regains Nasdaq compliance", "publisher": "investing.com", "type": "rss", "role": "primary", "official": false, "retrieved_at": "2026-11-17T05:45:41.114575Z", "published_at": "2026-11-16T22:36:36Z"}]}, "wireva:publication": {"name": "Контрактова", "domain": "kontraktova.com", "country": "UA", "url": "https://kontraktova.com/biznes/vivos-therapeutics-otrimala-zrostannia-viruchki-u-tretomu-kvartali-ta-vidnovila-vidpovidnist-vimogam-nasdaq/"}, "wireva:links": {"self": "https://wireva.mib.news/api/v1/items/d467cc98-d1e0-4bdb-bf2c-abd517db0d7a", "html": "https://wireva.mib.news/item/d467cc98-d1e0-4bdb-bf2c-abd517db0d7a/vivos-therapeutics-otrimala-zrostannia-viruchki-u-tretomu-kvartali-ta-vidnovila-vidpovidnist-vimogam-nasdaq/", "story": "https://wireva.mib.news/story/vivos-therapeutics-nasdaq-20261117/"}, "wireva:metrics": {"word_count": 173, "char_count": 1301, "reading_time_seconds": 93}}}}, "extra": {"wireva:languages": ["uk"], "wireva:status": "developing", "wireva:item_count": 1}}